Flagship Ventures Fund IV General Partner LLC current holdings: USA Other Stocks
Flagship Ventures Fund IV General Partner LLC reported $0.46 billion in shares no fund filing gives a ticker for, so this site has no page for them (listed in the US), 4 positions, in its Form 13F for the quarter ended 2016-06-30; the largest are SERES THERAPEUTICS INC, SYROS PHARMACEUTICALS INC, T2 BIOSYSTEMS INC.
- SERES THERAPEUTICS INC: Country of operation United States; Class COM; Shares 12,682,876; Value $368,438,000.
- SYROS PHARMACEUTICALS INC: Country of operation —; Class COM; Shares 4,806,656; Value $87,241,000.
- T2 BIOSYSTEMS INC: Country of operation —; Class COM; Shares 741,755; Value $5,852,000.
- ELEVEN BIOTHERAPEUTICS INC: Country of operation —; Class COM; Shares 1,466,417; Value $2,464,000.
Form 13F-HR as filed (SEC CIK 1508051): quarter ended 2016-06-30, filed 2016-08-15. The manager files one row per sub-manager; rows for the same security, class and put/call are added together.
Similar Firms
| Firm Name | Country | 13F Value | Holdings |
|---|---|---|---|
| Not available yet | |||